Switch theme
Sign up to access all valuation multiples
Beijing Scitop Bio-tech Co Ltd is engaged in production and sales of compound food additives, edible probiotic products and animal and plant micro-ecological preparations. The company engages in provision of biotechnology services, consulting, development, transfer; development and sale of stereotyped packaged food additives, compound food additives. Its products include Probio-M8 and Probio-M9.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Scitop Bio-tech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Scitop Bio-tech achieved revenue of $41.2M and an EBITDA of $16.9M.
Scitop Bio-tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scitop Bio-tech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $41.2M | n/a | XXX | XXX | XXX |
| Gross Profit | $25.3M | $26.4M | XXX | XXX | XXX |
| Gross Margin | 61% | NaN% | XXX | XXX | XXX |
| EBITDA | $16.9M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 41% | NaN% | XXX | XXX | XXX |
| Net Profit | $15.1M | $15.1M | XXX | XXX | XXX |
| Net Margin | 37% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Scitop Bio-tech's stock price is CNY 14 (or $2).
Scitop Bio-tech has current market cap of CNY 3.6B (or $502M), and EV of CNY 3.3B (or $448M).
See Scitop Bio-tech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $448M | $502M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Scitop Bio-tech has market cap of $502M and EV of $448M.
Scitop Bio-tech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Scitop Bio-tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Scitop Bio-tech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $448M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpScitop Bio-tech's NTM/LTM revenue growth is n/a
Scitop Bio-tech's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $31K for the same period.
Over next 12 months, Scitop Bio-tech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Scitop Bio-tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Scitop Bio-tech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $31K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 30% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scitop Bio-tech acquired XXX companies to date.
Last acquisition by Scitop Bio-tech was XXXXXXXX, XXXXX XXXXX XXXXXX . Scitop Bio-tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Scitop Bio-tech founded? | Scitop Bio-tech was founded in 2003. |
| Where is Scitop Bio-tech headquartered? | Scitop Bio-tech is headquartered in China. |
| How many employees does Scitop Bio-tech have? | As of today, Scitop Bio-tech has 402 employees. |
| Is Scitop Bio-tech publicy listed? | Yes, Scitop Bio-tech is a public company listed on SHE. |
| What is the stock symbol of Scitop Bio-tech? | Scitop Bio-tech trades under 300858 ticker. |
| When did Scitop Bio-tech go public? | Scitop Bio-tech went public in 2020. |
| Who are competitors of Scitop Bio-tech? | Similar companies to Scitop Bio-tech include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Scitop Bio-tech? | Scitop Bio-tech's current market cap is $502M |
| Is Scitop Bio-tech profitable? | Yes, Scitop Bio-tech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
